Topics

Companies Related to "Impacts of Aronia on Inflammation and the Gut Microbiome" [Most Relevant Company Matches] RSS

06:42 EST 18th January 2020 | BioPortfolio

Here are the most relevant search results for "Impacts of Aronia on Inflammation and the Gut Microbiome" found in our extensive corporate database of over 50,000 company records.

Showing "Impacts Aronia Inflammation Microbiome" Companies 1–25 of 345

Relevant

Microbiome Insights

Microbiome Insights, Inc. is a leading global provider of end-to-end services for microbiome DNA sequencing, including state-of-the-art bioinformatic analysis. Based in Vancouver, Canada, the company's customized suite of services enables researchers and clinicians to easily and effectively include microbiome analysis in studies across a range of human, an...


Microbiome Insights, Inc.

Microbiome Insights, Inc. is a global provider of end-to-end services for microbiome DNA sequencing and state-of-the-art bioinformatic analysis. Based in Vancouver, Canada, the company's customized suite of services enables researchers and clinicians to include microbiome analysis in studies across a range of human, animal, agricultural, and environmental ...

RondinX

Founded in 2016 by leading microbiome experts, RondinX has built a cutting-edge microbiome technology platform set to unlock the potential of microbiome therapeutics. RondinX technology, including its PTR (Peak-to-Trough) family of algorithms, exclusively licensed from YEDA (the commercial arm of the Weizmann Institute of Science), is a proprietary, cloud-...


Symbiotix Biotherapies, Inc.

Symbiotix Biotherapies, Inc. is a pioneering microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College. Symbiotix is developing a novel class of Treg-modulating therapeutics based on molecules derived from the human microbiome. ...

Seres Therapeutics Inc.

Seres Therapeutics Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome.

Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome.

BiomeBliss

Developed by MicroBiome Therapeutics LLC, BiomeBliss is a patented prebiotic dietary supplement designed to nourish, shift and protect the microbiome of the human digestive system. A powdered drink mix, BiomeBliss is made from natural plant-based ingredients. Clinical test results show BiomeBliss helps control hunger, promotes regularity, supports overall ...

MaaT Pharma

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leuk...

Gemelli Biotech

Gemelli Biotech is a specialty biotechnology company that strives to achieve a thriving global family of healthy individuals by unlocking the potential of the microbiome. Gemelli’s mission is to support the discovery of novel diagnostics and therapeutics for the human microbiome by bringing biotechnology innovations to market in a fiscally responsible...

SFA Therapeutics, Inc.

SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-KB mediated pathways. Chronic inflammation has been implicated in a wide range of diseases, including Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease ...

Kaleido Biosciences

Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maint...

Alivio Therapeutics

Alivio Therapeutics, an affiliate of PureTech Health (PRTC.L), is pioneering targeted disease immunomodulation to treat a range of chronic and acute inflammatory disorders. Targeted disease immunomodulation involves acting exclusively at the site of inflammation rather than systemically, to minimize impacts on the wider immune system and healthy tissue. To...

Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. Ritter is advancing human gut health research by exploring the metabolic capacity of gut microbiota and translating the functionality of these microbiome modulators into safe and effectiv...

Rebiotix Inc.

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for th...

Vedanta Biosciences, Inc.

Vedanta Biosciences is a clinical-stage microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived non-pathogenic bacteria. Vedanta’s proprietary capabilities include what is believed to be the largest collection of human-gut associated bacteria, assays and bioinformatics techniques for consortia des...

Commense, Inc.

Commense, Inc., an affiliate of PureTech Health (LSE: PRTC), is developing interventions for pediatric and maternal health based on a deep understanding of the microbiome and its fundamental role as the foundation for the development of immune tolerance. Commense is working with some of the world’s leading microbiome scientists, physicians, and resear...

Osel, Inc.

Osel, Inc., a privately held biotechnology company, is focused on the development and commercialization of a portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat medical conditions resulting from a disruption of the human microbiome. The company is a pioneer in the field of LBPs. In 2003, Osel became one of the first companies to receive ...

Aerocrine Inc

Aerocrine is a clinically based medical, technical company with headquarters in Stockholm, Sweden. It was founded in 1997 by scientists at the Karolinska Institute that first identified Nitric Oxide (NO) as a marker of inflammation. Aerocrine’s initial commitment is to develop NO analysis for asthma. The company holds a comprehensive patent portfolio in prioritized markets such as the European U...

CytoPherx, Inc.

CytoPherx was founded in July 2007 and is headquartered in Ann Arbor, Michigan. It is a venture backed, clinical stage medical device company addressing inflammation-based diseases and conditions. The company’s products are custom configurations of a proprietary selective cytopheresis-based inflammation modulating system.

Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes. Activation of this important biological target protects against a broad range of diseases associated with inflammation and oxidative stress. Reata is developing b...

EnteroBiotix

EnteroBiotix is harnessing the human microbiome to develop novel medicinal products that restore health and prevent disease. The company’s first focus is to unlock the full therapeutic potential intestinal microbiome transfer through two core product portfolios targeting gastrointestinal diseases and infections caused by bacteria such as C.difficile. ...

Probably Relevant

VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of dr...

Airway Therapeutics, Inc.

Airway Therapeutics, based in Cincinnati, OH, is a biopharmaceutical company developing a new class of biologics to break the injury cycle of inflammation for patients with respiratory and inflammatory diseases, beginning with the most vulnerable populations. The company is advancing the novel recombinant human protein rhSP-D, an engineered version of an endogenous protein that reduces inflammati...

Enterome Bioscience SA

Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as inflammatory bowel diseases, cancer, and metabolic diseases.

Synedgen Inc.

Synedgen Inc. is developing a new class of drugs with the ability to suppress inflammation, reduce infection and improve healing in the gastrointestinal tract and pulmonary tree and to reduce damage and inflammation due to chemical, radiological or physical damage using the science of glycomics - the study of complex sugar structure and function. Synedgen ...


More From BioPortfolio on "Impacts of Aronia on Inflammation and the Gut Microbiome"

Quick Search

Corporate Database Quicklinks